<DOC>
	<DOCNO>NCT01543451</DOCNO>
	<brief_summary>The main objective study obtain data efficacy elsiglutide prevent Chemotherapy Induced Diarrhea ( CID ) patient colorectal cancer receive 5-FU base chemotherapy ( FOLFOX4 FOLFIRI regimen ) comparison placebo .</brief_summary>
	<brief_title>Proof-of-Concept Study Cancer Patients Assess Efficacy Elsiglutide Preventing Chemotherapy-Induced Diarrhea</brief_title>
	<detailed_description />
	<mesh_term>Diarrhea</mesh_term>
	<criteria>1 . Written informed consent ; 2 . Male female patient ≥ 18 year age ; 3 . Confirmed diagnosis colorectal cancer ; 4 . Chemotherapy naïve patient ; 5 . Patient schedule receive FOLFOX4 FOLFIRI chemotherapy regimen accord follow scheme dosage ( 1st cycle ) : AGENT DOSE ROUTE/DURATION DAYS Oxaliplatin Irinotecan 85/180 mg m2 i.v . infusion/2h 1 FolinicAcid ( leucovorin ) 200 mg m2 i.v . infusion/2h 1+2 5Fluorouracil ( 5FU ) 400 mg m2 i.v . bolus 1+2 5Fluorouracil ( 5FU ) 600 mg m2 i.v . infusion/22h 1+2 6 . A performance status ≤ 2 accord Eastern Cooperative Oncology Group ( ECOG ) ; 7 . Nonfertile patient fertile patient ( male female ) use reliable contraceptive measure 8 . Female patient childbearing potential ; need negative pregnancy test screening . Inclusion criteria 18 verified screening . Inclusion criteria 8 reconfirm Day 1 . 1 . Inability understand study procedure and/or cooperate study Investigator ; 2 . Any investigational drug within 30 day enrollment study foreseen use investigational agent study ; 3 . Patient type ostomy ; 4 . Any previous radiotherapy abdomen pelvis ; 5 . Scheduled receive radiotherapy abdomen pelvis study ( Day 1 Day 14 ) ; 6 . Scheduled receive concomitant chemotherapeutic agent FOLFOX4 FOLFIRI agent ( Oxaliplatin , Irinotecan , Folinic acid , 5FU ) Day 1 Day 14 ; 7 . Previous use schedule receive monoclonal antibody ( e.g . bevacizumab , cetuximab , etc ) study ( From Day 1 Day 14 ) ; 8 . Major surgery within previous 3 week ; 9 . Any type condition lead chronic diarrhea , include limited inflammatory bowel disease ( e.g . ulcerative colitis Crohn 's disease ) , chronic diarrhea presume confirm infectious origin irritable bowel syndrome ; 10 . Any diarrhea 48 hour precede study drug administration ; 11 . Use antidiarrheal agent within 48 hour prior study drug administration ; 12 . Use laxatives within 7 day prior study drug administration ; 13 . Use antibiotic within 7 day prior study drug administration ; 14 . History chronic ( ≥ 30 consecutive day ) use laxatives ; 15 . Active ongoing systemic infection ; 16 . Lactating woman ; 17 . History hypersensitivity allergy drug compound potentially related investigational drug class ; 18 . Previous exposure GLP2 compound investigational drug class ; 19 . Abnormal laboratory value , include Aspartate aminotransferase ( AST ) ≥ 5 x upper limit normal Alanine aminotransferase ( ALT ) ≥ 5 x upper limit normal Bilirubin &gt; 2 mg/dL ( 34 μmol/L ) Creatinine &gt; 2 mg/dL ( 177 μmol/L ) Albumine &lt; 2 g/dL ( 20 g/L ) Neutrophils &lt; 1.5 x109/L Platelet count &lt; 100 x109/L ; 20 . Concomitant bleeding disorder ; 21 . Other serious concomitant illness , could interfere study ; 22 . Patient participate previous study elsiglutide ( ZP1846 ) . Exclusion criteria 19 1222 verify screen . Exclusion criteria 10 11 check Day 1 . Exclusion criterion 12 , 13 15 rechecked Day 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>